Changeflow GovPing Pharma & Drug Safety Anti-IgG Nanobodies Patent Granted to Max-Planck
Routine Rule Added Final

Anti-IgG Nanobodies Patent Granted to Max-Planck

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12600799B2 to Max-Planck-Gesellschaft on April 14, 2026 for novel anti-IgG nanobodies directed against rabbit or mouse IgG. The patent contains 11 claims classified under CPC C07K 16/42. The invention also covers methods for producing and using said nanobodies.

What changed

The USPTO granted patent US12600799B2 to Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. for novel anti-IgG nanobodies, specifically those directed against rabbit or mouse IgG. The patent includes 11 claims and covers methods for producing and using the nanobodies.

For entities developing nanobody technologies or antibody-related products, this granted patent establishes new intellectual property rights that may affect freedom-to-operate considerations in the nanobody research and development space.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Anti-IgG nanobodies

Grant US12600799B2 Kind: B2 Apr 14, 2026

Assignee

MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

Inventors

Dirk Görlich, Tino Pleiner

Abstract

The present invention relates to novel anti-IgG nanobodies, particularly nanobodies directed against rabbit or mouse IgG. Further, the invention relates to the use of said nanobodies and methods for producing them.

CPC Classifications

C07K 16/42 C07K 2317/22 C07K 2317/33 C07K 2317/569 C07K 2317/92

Filing Date

2018-10-11

Application No.

16754847

Claims

11

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600799B2

Who this affects

Applies to
Pharmaceutical companies Researchers Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent grants Nanobody development Antibody research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!